Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury

1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber

The purpose of this study is to determine safety and efficacy of pl-vegf165 ("Neovasculgen") for regeneration of peripheral nerve. Pl-vegf165 ("Neovasculgen") is the permitted in Russian Federation angiogenic medication that induce growth of new vessels and included in a complex therapy for patients with peripheral arterial diseases in Russia. It has also been shown to enhance nerve regeneration and muscle reinnervation in animals but these properties have not previously been studied in patients. Moreover, currently there is no method in clinical use to speed the rate of recovery after nerve injury. The objective of this study is to explore the ability of pl-vegf165 to benefit the treatment of patients with peripheral nerve injury. The investigators hypothesize that treatment with intraneural injections with pl-vegf165 after peripheral nerve reconstruction will accelerate nerve regeneration, reduce the period of denervation and improve muscle reinnervation and recovery in patients with peripheral nerve injury.

Study Overview

• Status: Unknown
• Conditions: Peripheral Nerve Injury
• Intervention / Treatment: Drug: Neovasculgen

Detailed Description

All patients enrolled into the study will receive standard surgery procedures indicated in accordance with medical care standards for the certain disease. Patients after nerve injury classified as neurotmesis will receive surgical repair of injured nerves what will be added by intraneural injections of pl-vegf165. Safety and efficacy of gene therapy will be assessed by physical examination, comprehensive laboratory tests over next 18 month after surgical nerve reconstruction.

• Study Type: Interventional
• Enrollment (Anticipated): 45
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Igor Plaksa; Phone Number: +79112171859; Email: i.plaksa2014@yandex.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with confirmed transection injury between shoulder and wrist
• Isolated injury of ulnar or median nerve (not mixed injury of several nerves)
• Nerve injuries which are amenable to direct end-to-end repair
• Length of the gap between of stumps of transected nerve no longer than 3,5 centimeters
• Early delayed (secondary) repair performed between 2 to 6 weeks after nerve injury

Exclusion Criteria:

• Length of the gap between of stumps of transected nerve more than 3,5 centimeters
• Simultaneous injury of several peripheral nerves
• Localization of nerve injury beyond of forearm
• Presence of neurological deficit preceding to nerve injury
• Systemic disease of connective tissue
• Myopathy
• Large surgical procedures planned for next one and a half year
• Presence of oncological diseases
• Pregnancy and breastfeeding
• Alcohol and drug addiction
• Patient ability to adhere strictly to the rules of the current clinical trial protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Neovasculgen 1; Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.	Drug: Neovasculgen
Experimental: Neovasculgen 2; Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.	Drug: Neovasculgen
Placebo Comparator: water for injections; Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disabilities of the Arm, Shoulder and Hand (DASH) Measure	The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure is a 30-item, self-report questionnaire designed to measure physical function and symptoms in patients with any or several musculoskeletal disorders of the upper limb. The questionnaire was designed to help describe the disability experienced by people with upper-limb disorders and also to monitor changes in symptoms and function over time. Testing has shown that the DASH performs well in both these roles.	540 days
Adverse events		540 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Medical Research Council (MRC) Scale for Muscle Strength	In this scale, muscle strength is graded on a scale from 0 to 5 depending on ability to make whole fall active range of motion and presence of muscle resistance	90 days;180 days; 270 days; 360 days; 450 days; 540 days
The Short Form (36) Health Survey	The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	90 days;180 days; 270 days; 360 days; 450 days; 540 days
Nerve conduction velocity	For electrodiagnostic assessment, nerve conduction velocity (NCV) was tested as motor and sensory. The results categorized according to the Yale sensory scale and the severity of sensation and function of the nerves was scored as follows: 0, no sensation; 1, decreased or abnormal sensation; 2, normal sensation.	180 days; 360 days; 540 days
Electromyography	For an EMG, a needle electrode was inserted through the skin into the muscle which injured nerve supplied. The presence, size and shape of the waveform registered and the ability of the muscle to respond when the nerves were stimulated. Also these results scored as follows: 0, no activity; 1, few or single movement; 2, partial activity; 3, full activity.	180 days; 360 days; 540 days

Collaborators and Investigators

• Sponsor: Human Stem Cell Institute, Russia
• Collaborators: Kazan Federal University

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Anticipated): March 1, 2016
• Study Completion (Anticipated): September 1, 2017

Study Registration Dates

• First Submitted: January 24, 2015
• First Submitted That Met QC Criteria: January 28, 2015
• First Posted (Estimate): February 2, 2015

Study Record Updates

• Last Update Posted (Estimate): February 2, 2015
• Last Update Submitted That Met QC Criteria: January 28, 2015
• Last Verified: January 1, 2015

More Information

Terms related to this study

• Keywords: Gene therapy; Peripheral nerve injury; Neurotmesis; Plasmid; Nerve regeneration therapy
• Additional Relevant MeSH Terms: Nervous System Diseases; Wounds and Injuries; Neuromuscular Diseases; Peripheral Nervous System Diseases; Trauma, Nervous System; Peripheral Nerve Injuries
• Other Study ID Numbers: Neurotmesis